These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 37866024)
1. Utilization of FDA approved treatments for neuromyelitis optica spectrum disorder in clinical practice: A survey study of academic neuroimmunologists. Thon JM; Sharkus R; Thakkar R; Hunter K; Siegler JE; Thon OR Mult Scler Relat Disord; 2023 Dec; 80():105076. PubMed ID: 37866024 [TBL] [Abstract][Full Text] [Related]
2. Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder. Clardy SL; Pittock SJ; Aktas O; Nakahara J; Isobe N; Centonze D; Fam S; Kielhorn A; Yu JC; Jansen J; Zhang I Neurol Ther; 2024 Jun; 13(3):535-549. PubMed ID: 38722571 [TBL] [Abstract][Full Text] [Related]
3. Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder. Wingerchuk DM; Zhang I; Kielhorn A; Royston M; Levy M; Fujihara K; Nakashima I; Tanvir I; Paul F; Pittock SJ Neurol Ther; 2022 Mar; 11(1):123-135. PubMed ID: 34773597 [TBL] [Abstract][Full Text] [Related]
4. International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab. Paul F; Marignier R; Palace J; Arrambide G; Asgari N; Bennett JL; Cree BAC; De Sèze J; Fujihara K; Kim HJ; Hornby R; Huda S; Kissani N; Kleiter I; Kuwabara S; Lana-Peixoto M; Law L; Leite MI; Pandit L; Pittock SJ; Quan C; Ramanathan S; Rotstein D; Saiz A; Sato DK; Vaknin-Dembinsky A Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37258412 [TBL] [Abstract][Full Text] [Related]
5. Recent advances in the treatment of neuromyelitis optica spectrum disorders. Romeo AR Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature. Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580 [TBL] [Abstract][Full Text] [Related]
7. Satralizumab in the treatment of neuromyelitis optica spectrum disorder. Duchow A; Bellmann-Strobl J Neurodegener Dis Manag; 2021 Feb; 11(1):49-59. PubMed ID: 33167776 [TBL] [Abstract][Full Text] [Related]
8. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder. Nie T; Blair HA CNS Drugs; 2022 Oct; 36(10):1133-1141. PubMed ID: 36070074 [TBL] [Abstract][Full Text] [Related]
9. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder. Fung S; Shirley M CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107 [TBL] [Abstract][Full Text] [Related]
10. Inebilizumab-cdon: USFDA Approved for the Treatment of NMOSD (Neuromyelitis Optica Spectrum Disorder). Ali F; Sharma K; Anjum V; Ali A Curr Drug Discov Technol; 2022; 19(1):e140122193419. PubMed ID: 34011260 [TBL] [Abstract][Full Text] [Related]
11. Satralizumab for the Treatment of Neuromyelitis Optica Spectrum Disorders. Gao Y; Zhang B; Yang J Ann Pharmacother; 2021 Sep; 55(9):1167-1171. PubMed ID: 33246373 [TBL] [Abstract][Full Text] [Related]
12. Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder. Wallach AI; Tremblay M; Kister I Neurol Clin; 2021 Feb; 39(1):35-49. PubMed ID: 33223088 [TBL] [Abstract][Full Text] [Related]
13. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders. Duchow A; Paul F; Bellmann-Strobl J Expert Opin Biol Ther; 2020 Sep; 20(9):1061-1072. PubMed ID: 32228250 [TBL] [Abstract][Full Text] [Related]
14. A Clinical Approach to Existing and Emerging Therapeutics in Neuromyelitis Optica Spectrum Disorder. Yong HYF; Burton JM Curr Neurol Neurosci Rep; 2023 Sep; 23(9):489-506. PubMed ID: 37540387 [TBL] [Abstract][Full Text] [Related]
15. Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model. Lazzaro C; Mazzanti NA; Rossi S; Parazzini F Expert Rev Pharmacoecon Outcomes Res; 2023; 23(10):1185-1200. PubMed ID: 37795872 [TBL] [Abstract][Full Text] [Related]